Bioavailability and Bioequivalence of Two Risdiplam Tablets in Healthy Participants
Status:
Recruiting
Trial end date:
2022-04-18
Target enrollment:
Participant gender:
Summary
The study is a randomized, single oral dose, crossover study in up to three parts to
investigate the relative bioavailability and bioequivalence of two different formulations of
risdiplam 5 mg (dispersible tablets) versus the current risdiplam oral solution formulation
in healthy male and female participants. The effect of food on these two dispersible tablets
and the current oral solution will be studied, as well as the effect of omeprazole on the
dispersible tablets.